Arca
Skip to content
Tools
Tools

PTAFR: Platelet-activating factor receptor

Receptor for platelet activating factor, a chemotactic phospholipid mediator that possesses potent inflammatory, smooth-muscle contractile and hypotensive activity.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on PTAFR, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Rupatadine

Phase 30

    Phase 21

    • Minopafant ion

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      RupatadineApprovedFujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Small moleculeAntagonistPlatelet activating factor receptor antagonist5
      Minopafant ionPhase 2—Small moleculeAntagonistPlatelet activating factor receptor antagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 5 in all, from ClinicalTrials.gov.
      Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.RupatadinePhase 2 / Phase 3Not yet recruitingTanta UniversityOct 28, 2026
      Rupatifen Fumarate Capsules in Patients With Seasonal Allergic RhinitisRupatadinePhase 3RecruitingFujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Jul 17, 2026
      Rupatadine in Patients With Ulcerative ColitisRupatadinePhase 2RecruitingAlexandria UniversityJul 15, 2025
      Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control ParticipantsRupatadinePhase 1RecruitingNoucor Health S.A.Nov 27, 2024
      Effect of Some Drugs on Rheumatoid Arithritis ActivityRupatadinePhase 3RecruitingSherief Abd-ElsalamDec 10, 2018

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Allergic disease0.37
      • Cold urticaria0.28
      • Chronic idiopathic urticaria0.28
      • Mastocytosis0.18
      • Hypothyroidism0.12
      • Neoplasm0.11
      • Ovarian carcinoma0.11
      • Infection0.09

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL250, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P25105, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.